Your browser doesn't support javascript.
loading
Impact of pneumococcal conjugate vaccination on hospitalized childhood pneumonia in Taiwan.
Lee, Jian-Te; Lin, Jou-Wei; Chen, Ho-Min; Wang, Chen-Yu; Lu, Chun-Yi; Chang, Luan-Yin; Huang, Li-Min.
Afiliación
  • Lee JT; National Taiwan University Hospital, Yunlin Branch, Yunlin, Taiwan.
  • Lin JW; National Taiwan University Hospital, Yunlin Branch, Yunlin, Taiwan.
  • Chen HM; National Taiwan University, Taipei, Taiwan.
  • Wang CY; National Taiwan University Hospital, Yunlin Branch, Yunlin, Taiwan.
  • Lu CY; National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Chang LY; National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan. lychang@ntu.edu.tw.
  • Huang LM; National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan.
Pediatr Res ; 92(4): 1161-1167, 2022 10.
Article en En | MEDLINE | ID: mdl-34937875
ABSTRACT

BACKGROUND:

A national 13-valent pneumococcal conjugate vaccine (PCV13) catch-up program among children aged 2-5 years in 2013, before routine infant immunization in 2015, successfully reduced serotype 19A-related invasive pneumococcal diseases in Taiwan. We aimed to investigate its impact on hospitalized childhood pneumonia.

METHODS:

We analyzed the National Health Insurance Research Database, 2001-2017, for hospitalized children aged <18 years with the diagnoses of all-cause pneumonia, lobar/pneumococcal pneumonia, and pneumococcal parapneumonic diseases. The study period was divided into 2001-2005 (pre-PCV), 2006-2012 (private sectors), and 2013-2017 (universal PCV13 vaccination).

RESULTS:

On pneumococcal parapneumonic diseases, the national PCV13 vaccination program was associated with an immediate decline in 2-4-year-old children and significant decreasing trends in all ages. The incidence rate ratios of 2016-2017/2011-2012 were 0.16 (95% confidence interval [CI], 0.06-0.40) and 0.18 (95% CI, 0.13-0.23) in children aged < 2 and 2-4 years, respectively. We observed an increase of lobar/pneumococcal pneumonia cases after an early decline. The intensive/invasive medical needs and the fatality of all-cause pneumonia decreased significantly in children of all ages.

CONCLUSIONS:

Pneumococcal parapneumonic diseases and the disease burden of lobar/pneumococcal pneumonia and lower respiratory tract infections declined after the national PCV13 vaccination program. IMPACT The impact study of the PCV13 immunization program on childhood pneumonia in Asian countries remained limited. The unique PCV13 immunization program in Taiwan, catch-up before primary infantile series, reduced severe childhood pneumococcal pneumonia at 5 years post PCV13. The intensive and invasive medical needs and fatality of all-cause pneumonia decreased significantly in children of all ages. We observed an increase in lobar/pneumococcal pneumonia after an early decline.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones Neumocócicas / Neumonía Neumocócica Tipo de estudio: Incidence_studies / Prognostic_studies Límite: Child / Child, preschool / Humans / Infant País/Región como asunto: Asia Idioma: En Revista: Pediatr Res Año: 2022 Tipo del documento: Article País de afiliación: Taiwán

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones Neumocócicas / Neumonía Neumocócica Tipo de estudio: Incidence_studies / Prognostic_studies Límite: Child / Child, preschool / Humans / Infant País/Región como asunto: Asia Idioma: En Revista: Pediatr Res Año: 2022 Tipo del documento: Article País de afiliación: Taiwán